Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies

June 27, 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Data on 1077 patients from 8 clinics in 7 US cities were presented. These data were collected between 10/98 to 12/98 by using a questionnaire that was completed by the treating physician in the presence of the patient. The data on lipodystrophy were then classified on the basis of the severity of physical findings and number of areas affected. Of all respondents, 51% had no physical manifestations (level A), 30% had 1-2 mild/moderate signs including central adiposity, fat loss in extremities or hips (level B, mild); 13% had 3-4 mild/moderate signs including facial changes (level C, moderate) and 6% had 5-6 signs, some severe, including dorsocervical fat pad (level D, severe).

The following table provides frequency of impaired glucose tolerance (IGT) and median values for plasma triglycerides (TG) and cholesterol (CH) concentrations in these categories:

  Severity Level
A B C D
IGT (%) 5 6 9 17
Plasma CH (mg/dL) 192 203 206 212
Plasma TG (mg/dL) 187 236 260 321

Severity of lipodystrophy was associated with following factors after adjusting for the duration since HIV diagnosis: age, lowest ever CD4 count and duration of therapy for stavudine, lamivudine, indinavir and saquinavir.

This cross-sectional study suggests that causes of lipodystrophy syndrome may not be limited to protease inhibitor therapy. Other factors such as time since HIV diagnosis, immune factors, age and other antiretroviral agents may play a role in causing fat redistribution. The limitation of the study was that the classification of severity was based on subjective criteria only.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Abstract: Description of Lipodystrophy in the HIV Outpatient Study (HOPS)
Authored by: D. J. Ward

See Also
An HIVer's Guide to Metabolic Complications
More Research on Lipodystrophy and Other Metabolic Complications
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement